(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.47%) $83.46
(-1.16%) $1.619
(-0.04%) $2 346.30
(0.76%) $27.46
(0.28%) $924.70
(-0.03%) $0.934
(-0.06%) $11.02
(-0.05%) $0.800
(0.00%) $92.17
@ $4.00
发出时间: 14 Feb 2024 @ 03:29
回报率: -40.25%
Live Chart Being Loaded With Signals
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues...
Stats | |
---|---|
今日成交量 | 65 262.00 |
平均成交量 | 372 577 |
市值 | 4.69M |
EPS | $0 ( 2024-04-02 ) |
下一个收益日期 | ( $-3.33 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0200 |
ATR14 | $0.0500 (2.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-08 | Runge Jeffrey W. | Buy | 470 | Options (right to buy) |
2023-11-08 | Albanna Rowena | Buy | 4 702 | Options (right to buy) |
2023-11-08 | Nelson Charles Athle | Buy | 470 | Options (right to buy) |
2023-11-08 | Albanna Amro A. | Buy | 9 404 | Options (right to buy) |
2023-11-08 | Pankovcin Corinne | Buy | 4 702 | Options (right to buy) |
INSIDER POWER |
---|
26.52 |
Last 84 transactions |
Buy: 1 934 500 | Sell: 1 185 103 |
音量 相关性
ADiTx Therapeutics, Inc. 相关性 - 货币/商品
ADiTx Therapeutics, Inc. 财务报表
Annual | 2023 |
营收: | $645 176 |
毛利润: | $-654 243 (-101.41 %) |
EPS: | $-107.10 |
FY | 2023 |
营收: | $645 176 |
毛利润: | $-654 243 (-101.41 %) |
EPS: | $-107.10 |
FY | 2022 |
营收: | $933 715 |
毛利润: | $166 936 (17.88 %) |
EPS: | $-608.04 |
FY | 2021 |
营收: | $105 034 |
毛利润: | $27 055.00 (25.76 %) |
EPS: | $-6.72 |
Financial Reports:
No articles found.
ADiTx Therapeutics, Inc.
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。